- Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes
- The study showed at least three primary positive outcomes, including weight loss and improved triglyceride and cholesterol levels, with lower doses of DehydraTECH-CBD achieving the most optimum outcome
- The success of this study inches Lexaria closer to capitalizing on the potential of the diabetes drug market, estimated at $63.1 billion in 2021
- It also points to the technology’s effectiveness, particularly following the success of the company’s most ambitious clinical study, HYPER-H21-4, demonstrating the potential of DehydraTECH-CBD for the treatment of hypertension
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. The company’s patented DehydraTECH(TM) drug delivery platform technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients. They recently completed its diabetes animal model study DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes. The study produced at least three positive outcomes in what Lexaria’s management described as “encouraging,” further indicating many prospective benefits worthy of further investigation together down the line (https://cnw.fm/fw4H8).
The study, which involved 32 male Zucker (“ZDF”) rats- 24 obese and eight lean, saw the administration of Lexaria’s “DehydraTECH-CBD 2.0” formulations at either 30 mg/Kg or 100 mg/Kg of body weight. Following initial positive early responses witnessed, the study, which was to last for four weeks, was…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
